Wyeth appealing two hormone verdicts

Another Prempro judgment, another appeal. An Arkansas jury yesterday ordered Wyeth and Upjohn to pay more than $27 million in punitive damages; that would allocate out to $19.4 million from Wyeth and $7.8 million from Upjohn, a Pfizer unit. That's on top of $2.75 million in compensatory damages. The jury found that the plaintiff developed breast cancer from taking the companies' hormone-replacement therapies.

By late afternoon, Wyeth had announced it plans to appeal the jury verdicts. "There is no basis in fact or law for this award...We will pursue several post-trial motions and will ultimately appeal the entire case if necessary," Wyeth's lawyer said.

Meanwhile, Wyeth is also appealing a Nevada court's ruling in a similar hormone-replacement case. A jury awarded three women $134 million in the case; though the judge then cut that award to $58 million, the company filed an appeal, saying that the verdict itself was "irreparably flawed and fraught with error." The company faces thousands of other hormone-replacement cases across the country.

- see the brief in the Wall Street Journal
- read the CNN Money report about the Arkansas appeal
- check out the Nevada coverage in the Reno Gazette-Journal

Related Articles:
Court dismisses lawsuit on Wyeth's Prempro. Report
Jury fines Wyeth $134.5M in hormone suit. Report
Wyeth asks judge to cut $134M award. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.